ACRIVON THERAPEUTICS CORPORATE R&D AND KOL EVENT - ACRIVON THERAPEUTICS INC

Explicit Guidance:

• No specific revenue, earnings, margin, or cash flow guidance provided for any fiscal period.
• No explicit financial guidance regarding share count, dividends, or buybacks.
• Capital allocation plan: The company intends to fundraise as part of routine operations, with planning to execute this "sometime next year" (likely FY2026).
• Asset ownership: The acquired JAK1 asset (ACR525) and PKC theta asset are wholly owned with "no milestone or royalty obligations."

Business-Segment Outlook:

• Phase 2 Readiness & Timing: ACR525 (oral JAK1 inhibitor) is "phase 2 ready" with an initial target indication of Eosinophilic Esophagitis (EOE). A phase 2 trial is expected to commence shortly, with a typical duration of 12 to 20 weeks.
• Trial Design Expectations: Management is considering a small sample size (15–20 patients for a single-arm or 25 patients per arm for placebo-controlled) utilizing early endpoints like eosinophil counts and biopsy histology, which may show normalization by 16 weeks.
• Combination Strategy: The company plans to profile ACR525 against IL-23 antagonists and TNF antagonists to identify synergistic combination opportunities, leveraging the AP3 platform for unbiased pathway mapping.
• Preclinical PKC Theta: The acquired preclinical PKC theta inhibitor program is positioned to be combined with ACR525 due to converging NF-kappa B and STAT pathways, expanding potential indications beyond EOE.
• Product Formulation: ACR525 has two oral formulations (capsule and tablet) with a "bridge study" confirming comparability; the formulation is designed for easy swallowing and high local concentration in the esophageal lining.
• Pipeline Expansion: The pipeline now incorporates the INI (Inflammatory and Immune) franchise, complementing existing assets like ACR2316 (PK-MET inhibitor) and ACR7280 (CDK11 inhibitor).

Market and Competitive Outlook:

• EOE Market Growth: EOE incidence has increased over 500% in the past 30 years (average annual growth >14%); US incidence is estimated at 120,000 new patients annually with a prevalence of over 500,000.
• Unmet Need: Current first-line therapies (PPIs, swallowed corticosteroids) show suboptimal response rates (>50% non-responders) and adherence issues; biologics like dupilumab require frequent injections and are second-line only.
• Competitive Positioning: ACR525 is positioned to fill the gap for a highly selective, once-daily oral therapy, potentially serving as a first-line treatment or immediate follow-up to PPIs, unlike the injectable nature of dupilumab.
• Differentiation: The asset demonstrates broader anti-inflammatory effects than dupilumab (inhibiting IL-9, IL-15, oncostatin M, TSLP) and distinct safety profiles compared to other JAK inhibitors (e.g., filgotinib) due to superior selectivity against JAK2/JAK3/TIK2.
• Commercialization Strategy: Management anticipates positioning the drug for long-term, potentially lifelong therapy, emphasizing the convenience of oral dosing for chronic disease management.

Macro / Industry Outlook:

• Regulatory Environment: Management expresses hope that the high degree of JAK1 selectivity and lack of pro-apoptotic signaling (specifically no BAD activation) could lead to a differentiated safety label, potentially avoiding or reducing "black box warnings" associated with current JAK inhibitors.
• Platform Validation: The AP3 platform is highlighted as a structural advantage for the INI space, capable of identifying drug-centric mechanisms without reliance on genetic alterations, positioning the company favorably against peers using genetic-centric AI.

Strategic Initiatives:

• Acquisition Execution: Successfully executed the acquisition of two INI assets (ACR525 and a preclinical PKC theta program) to fulfill the strategic narrative of leveraging the AI-driven AP3 platform in the inflammatory space.
• Platform Expansion: Continued development of proprietary tools for network mapping, pathway mapping, and patient responder prediction to identify rational drug combinations before clinical entry.
• Data Utilization: Plan to utilize mass spectrometry-based AP3 PD assays as early clinical endpoints in future trials, similar to the approach used in the ACR2316 oncology program.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: While hopeful for a differentiated safety profile, management explicitly states that black box warnings or labeling decisions are "ultimately a regulatory decision" and depend on the safety database generated during future trials.
• Clinical Execution Risks: The reliance on small sample sizes and early biomarkers for phase 2 success carries inherent risk if early endpoints do not correlate perfectly with long-term clinical benefit.
• Safety Liabilities: Despite preclinical data suggesting no activation of pro-apoptotic BAD signaling (linked to rhabdomyolysis in other JAK inhibitors), the ultimate safety profile in humans remains unproven.
• Market Competition: Continued dominance of established biologics and potential entry of new oral JAK inhibitors or IL-23 antagonists in the EOE space.

Management Tone on the Future:

• Confidence Level: High confidence and excitement; repeated use of terms like "super excited," "highly differentiated," and "strategic narrative" indicates strong belief in the platform and asset quality.
• Hedges: Management carefully frames safety expectations as "hopeful" rather than guaranteed, acknowledging regulatory finality.
• Strategic Clarity: Tone reflects a deliberate, planned execution of a long-stated strategy to enter the INI space, contrasting with opportunistic acquisitions.

Miscellaneous:

• Financial Runway: No specific cash runway numbers provided, but management confirmed plans to fundraise "sometime next year."
• Key Opinion Leader Engagement: Strong emphasis on KOL validation regarding EOE pathophysiology, treatment algorithms, and the specific unmet need for oral therapies.
• Data Presentation: Management plans to present late-breaking oral plenary data on ACR2316 at the upcoming Triple Meeting in Barcelona.